Pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC with PD-L1 tumor proportion score ≥50%: KEYNOTE-598 3-year follow-up

被引：2

作者：

Abreu, D. Rodriguez ^{[1
]}

Reck, M. ^{[2
]}

Sendur, N. ^{[3
,4
]}

Park, K. ^{[5
]}

Lee, D. H. ^{[6
]}

Cicin, I. ^{[7
]}

Yumuk, P. F. ^{[8
]}

Orlandi, F. J. ^{[9
]}

Leal, T. A. ^{[10
]}

Soparattanapaisarn, N. ^{[11
]}

Langleben, A. ^{[12
]}

Califano, R. ^{[13
,14
]}

Medgyasszay, B. ^{[15
]}

Hsia, T-C. ^{[16
,17
]}

Otterson, G. A. ^{[18
]}

Woods, T. ^{[19
]}

Jensen, E. ^{[19
]}

Samkari, A. ^{[19
]}

Boyer, M. ^{[20
]}

机构：

[1] Univ Las Palmas Gran Canaria, Complejo Hosp Univ Insular Maternoinfant Gran Can, Las Palmas Gran Canar, Spain

[2] German Ctr Lung Res, Airway Res Ctr North, LungenClin, Grosshansdorf, Germany

[3] Ankara Yildirim Beyazit Univ, Fac Med, Ankara, Turkey

[4] Ankara Yildirim Beyazit Univ, Ankara City Hosp, Ankara, Turkey

[5] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea

[6] Asan Med Ctr, Seoul, South Korea

[7] Trakya Univ, Edirne, Turkey

[8] Marmara Univ, Sch Med, Istanbul, Turkey

[9] Orlandi Oncol, Providencia, Chile

[10] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA

[11] Mahidol Univ, Siriraj Hosp, Bangkok, Thailand

[12] McGill Univ, St Marys Hosp ODIM, Dept Oncol, Montreal, PQ, Canada

[13] Univ Manchester, Christie NHS Fdn Trust, Manchester, Lancs, England

[14] Univ Manchester, Div Canc Sci, Manchester, Lancs, England

[15] Veszprem Cty Lung Hosp, Farkasgyepu, Hungary

[16] China Med Univ, Taichung, Taiwan

[17] China Med Univ Hosp, Taichung, Taiwan

[18] Ohio State Univ, James Comprehens Canc Ctr, Columbus, OH USA

[19] Merck & Co Inc, Kenilworth, NJ USA

[20] Chris OBrien Lifehouse, Camperdown, NSW, Australia

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷

关键词：

D O I：

10.1016/j.annonc.2022.02.015

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

6MO

引用

页码：S30 / S31

页数：2

共 46 条

[1] Pembrolizumab Plus Ipilimumab or Placebo in 1L Metastatic NSCLC with PD-L1 Tumor Proportion Score (TPS) ≥50%: KEYNOTE-598
Boyer, M.
Mclean, J.
Xu, L.
Samkari, A.
Carbone, D.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S462 - S462
[2] Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo as 1L Therapy for Metastatic NSCLC of PD-L1 TPS ≥50%: KEYNOTE-598
Boyer, M.
Sendur, M. A. N.
Rodriguez-Abreu, D.
Park, K.
Lee, D. H.
Cicin, I.
Yumuk, P. F.
Orlandi, F.
Leal, T.
Molinier, O.
Soparattanapaisam, N.
Langleben, A.
Califano, R.
Medgyasszay, B.
Hsia, T.
Otterson, G.
Xu, L.
Piperdi, B.
Samkari, A.
Reck, M.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S61 - S62
[3] Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study
Boyer, Michael
Sendur, Mehmet A. N.
Rodriguez-Abreu, Delvys
Park, Keunchil
Lee, Dae Ho
Cicin, Irfan
Yumuk, Perran Fulden
Orlandi, Francisco J.
Leal, Ticiana A.
Molinier, Olivier
Soparattanapaisarn, Nopadol
Langleben, Adrian
Califano, Raffaele
Medgyasszay, Balazs
Hsia, Te-Chun
Otterson, Gregory A.
Xu, Lu
Piperdi, Bilal
Samkari, Ayman
Reck, Martin
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (21) : 2327 - +
[4] Health-related quality of life for pembrolizumab (pembro) plus ipilimumab (ipi) versus pembro plus placebo in patients with metastatic NSCLC with PD-L1 tumor proportion score ≥ 50%: KEYNOTE-598.
Sendur, Mehmet Nahit
Reck, Martin
Rodriguez-Abreu, Delvys
Park, Keunchil
Lee, Dae Ho
Cicin, Irfan
Yumuk, Perran Fulden
Orlandi, Francisco J.
Leal, Ticiana A.
Molinier, Olivier
Soparattanapaisarn, Nopadol
Langleben, Adrian
Califano, Raffaele
Medgyasszay, Balazs
Hsia, Te-Chun
Otterson, Gregory Alan
Xu, Lu
Burke, Thomas A.
Samkari, Ayman
Boyer, Michael J.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[5] 5-Year Survival of Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With PD-L1 Tumor Proportion Score <1%
Gadgeel, S.
Rodriguez-Abreu, D.
Halmos, B.
Garassino, M. C.
Kurata, T.
Cheng, Y.
Jensen, E.
Shamoun, M.
Rajagopalan, K.
Paz-Ares, L.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S77 - S78
[6] KEYNOTE-024 Update: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced NSCLC with PD-L1 Tumor Proportion Score ≥50%
Brahmer, J.
Rodriguez-Abreu, D.
Robinson, A.
Hui, R.
Csoszi, T.
Fulop, A.
Gottfried, M.
Peled, N.
Tafreshi, A.
Cuffe, S.
O'Brien, M.
Rao, S.
Hotta, K.
Riccio, A.
Yang, J.
Pietanza, M. C.
Reck, M.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S153 - S153
[7] Pembrolizumab vs docetaxel for previously treated advanced NSCLC with a PD-L1 tumor proportion score (TPS) 1%-49%; Results from KEYNOTE-010.
Garon, Edward B.
Herbst, Roy S.
Kim, Dong-Wan
Felip, Enriqueta
Perez-Gracia, Jose Luis
Han, Ji-Youn
Kim, Joo-Hang
Arvis, Catherine Dubos
Ahn, Myung-Ju
Majem, Margarita
Fidler, Mary J.
Gubens, Matthew A.
Castro, Gilberto
Garrido, Marcelo
Shentu, Yue
Im, Ellie
Lubiniecki, Gregory M.
Baas, Paul
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[8] Real-World Time on Treatment with First-Line Pembrolizumab Monotherapy for Advanced NSCLC with PD-L1 Expression ≥ 50%: 3-Year Follow-Up Data
Velcheti, Vamsidhar
Hu, Xiaohan
Li, Yeran
El-Osta, Hazem
Pietanza, M. Catherine
Burke, Thomas
CANCERS, 2022, 14 (04)
[9] Real-world time on treatment (rwToT) with first-line pembrolizumab monotherapy in PD-L1 TPS ≥50% advanced NSCLC: 3-year follow-up data
Velcheti, V.
Hu, X.
Li, Y.
Burke, T.
Piperdi, B.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S755 - S755
[10] Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma (aHCC): 3-year follow-up of the phase 2 KEYNOTE-224 study.
Borbath, Ivan
Van Laethem, Jean-Luc
Karwal, Mark
Verslype, Chris
Van Vlierberghe, Hans
Kardosh, Adel
Bergamo, Francesca
Stal, Per
Sarker, Debashis
Palmer, Daniel H.
Edeline, Julien
Cattan, Stephane
Kudo, Masatoshi
Cheng, Ann-Lii
Ogasawara, Sadahisa
Siegel, Abby B.
Hatogai, Ken
Wang, Anran
Vogel, Arndt
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 4 5 →